Tolvaptan Phase 3 Efficacy and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Frank Czerwiec, MD, PhD
Otsuka Pharmaceutical Development & Commercialization, Inc.
Study Director - Osamu Sato
Otsuka Pharmaceutical Corporation, Ltd. Japan
Study Director - Vicente Torres, MD, PhD
Mayo Medical Center
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
133 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Hospital Municipal de Vicente Lopez, Dr Bernardo Houssay
Buenos Aires, Argentina
- Hosptial Universitario Austral
Buenos Aires, Argentina
- Instituto de Nefrología, Nefrology Sa
Buenos Aires, Argentina
- Hospital Privado-Centro Medico de Cordoba
Córdoba, Argentina
- Sanatorio Allende
Córdoba, Argentina
- Queen Elizebeth Hospital
Adelaide, Australia
- Royal Adelaide Hospital
Adelaide, Australia
- Princess Alexandra Hospital
Brisbane, Australia
- Melbourne Renal Research Group
Melbourne, Australia
- Royal Melbourne Hospital
Melbourne, Australia
- Royal Perth Hospital
Perth, Australia
- Royal North Shore Hospital
Sydney, Australia
- Westmead Hospital
Sydney, Australia
- Uz Brussel
Brussels, Belgium
- Ucl-St Luc
Brussels, Belgium
- Uz Gent
Ghent, Belgium
- Queen Elizabeth Ii Health Science Center, Division of Nephrology
Halifax, Nova Scotia, Canada
- Hospital Du Sacre- Coeur de Montreal
Montreal, Quebec, Canada
- Royal Victoria Hospital
Montreal, Quebec, Canada
- Herlev Amtssygehus
Herlev, Denmark
- Odense Universitetshospital
Odense, Denmark
- Chu-Hopital Pellegrin
Bordeaux, France
- Chu - Hôpital Clémenceau
Caen, France
- Hôpital Edouard Herriot
Lyon, France
- Hôpital de la Conception
Marseille, France
- Chu - Hôpital Lapeyronie
Montpellier, France
- Hopital Bichat-Claude Bernard
Paris, France
- Centre Hospitalier Universitaire
Reims, France
- Chu - Hôpital Nord
Saint-Etienne, France
- Hopital Rangueil
Toulouse, France
- Universitätsklinikum Carl Gustav Carus
Dresden, Germany
- Nephrologische Gemeinschaftspraxis/dialysezentrum
Düsseldorf, Germany
- Klinik Für Nieren- Und Hochdruckkrankheiten
Essen, Germany
- Universitätsklinikum Freiburg
Freiburg im Breisgau, Germany
- Universitätskliniken Heidelberg
Heidelberg, Germany
- Uh Erlangen/nürnberg
Nuremberg, Germany
- Ospedali Riuniti Di Bergamo
Bergamo, Italy
- Università Vita E Salute, Ospedale San Raffaele
Milan, Italy
- Policlinico Di Modena
Modena, Italy
- Policlinico
Naples, Italy
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Jan 2007
- Primary completion
- 31 Jan 2012
- Completion
- 31 Jan 2012
- Last update posted
- 2 Jul 2017
- Registered enrollment
- 1,445
- Registry id
- NCT00428948
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.